Selective inhibition of low affinity IgE receptor (CD23) processing.
A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23). Increased activity is obtained by appropriate substitution at the alpha-position, whilst selectivity is gained by use of a P1' benzyl group in conjunction with a C-terminal primary amide.
Bailey
S
S
SmithKline Beecham Pharmaceuticals, Epsom, Surrey, UK.
Bolognese
B
B
Buckle
D R
DR
Faller
A
A
Jackson
S
S
Louis-Flamberg
P
P
McCord
M
M
Mayer
R J
RJ
Marshall
L A
LA
Smith
D G
DG
D006877:Hydroxamic Acids / Q000737:chemistry / Q000494:pharmacology*; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology; D011499:Protein Processing, Post-Translational / Q000187:drug effects*; D017455:Receptors, IgE / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000737:chemistry / Q000494:pharmacology
D006877:Hydroxamic Acids; D011480:Protease Inhibitors; D017455:Receptors, IgE; D013876:Thiophenes; D010649:Phenylalanine; C080985:batimastat